Monitor for OSRH's election notice to convert the equity put into convertible notes, which would trigger a 20-business-day closing period. The fixed conversion prices well below the likely market price (given delisting risk) signal deep distress. Watch for Nasdaq listing status updates and any further management departures.
Price Chart
Executive Summary
OSR Health amended its existing license agreement with BCM Europe AG to add a convertible note option as an alternative settlement mechanism for BCME's $15M equity put option, triggered by a Nasdaq delisting determination on August 19, 2026. The amendment allows OSRH to issue up to $15M in convertible notes in four tranches at fixed conversion prices of approximately $2.00, $3.00, $4.00, and $5.00 per share, providing a financing backstop amid delisting risk. This follows the recent departure of the Chief Scientific Officer, signaling ongoing management and operational distress.
Key Financial Metrics
Key Facts
- OSR Health holds a put option requiring BCM Europe AG to purchase up to $15,000,000 of its common stock under the existing license agreement.
- Amendment No. 1 adds a convertible note option allowing OSRH to issue up to $15,000,000 in convertible notes in four tranches of $3,750,000 each.
- Conversion prices are fixed at approximately $2.00, $3.00, $4.00, and $5.00 per share, subject to Nasdaq's Minimum Price rule but not subject to reset.
- The amendment explicitly acknowledges a Nasdaq delisting determination issued on August 19, 2026 as a material subsequent development.
- Chief Scientific Officer Dr. Constance Hoefer resigned effective September 30, 2026, 14 days before this amendment was signed.
- BCME has identified a third-party purchaser and must deliver a binding commitment before OSRH can elect the note option.
Financial Impact
Up to $15,000,000 in potential convertible note issuance at fixed conversion prices of $2.00-$5.00 per share, representing significant potential dilution to existing common shareholders.
Risk Factors
- Potential delisting from Nasdaq, which could trigger further adverse financing terms and loss of market access.
- Significant dilution from conversion of up to $15M in notes at low fixed prices ($2-$5/share).
- Execution risk: the note purchase requires a third-party buyer identified by BCME; failure to close would reinstate the original equity put option.
- Recent CSO departure suggests possible broader management instability.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-110051 |
| Document: ea030872501ex10-1.htm | 0001213900-26-110051 |
| Document: 0001213900-26-110051-index-headers.html | 0001213900-26-110051 |
| Document: 0001213900-26-110051-index.html | 0001213900-26-110051 |
| Document: 0001213900-26-110051.txt | 0001213900-26-110051 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 8-K | $0.1165 | awaiting T+20 | — | $0.2070 (−77.68%) |
Oct 2, 2026 25d ago | 8-K | $0.2410 | awaiting T+20 | — | $0.2070 (−14.11%) |
Aug 28, 2026 8w ago | 8-K | $0.1165 $0.1165 | · 0.00% | ▲ +0.26% | $0.2070 (−77.68%) |
Aug 25, 2026 9w ago | 8-K | $0.1165 $0.1165 | · 0.00% | ▲ +0.98% | $0.2070 (−77.68%) |
Aug 19, 2026 9w ago | 8-K | $0.2949 $0.1165 | ▲ +60.50% | ▲ +60.50% | $0.2070 (+29.81%) |
Jul 31, 2026 12w ago | 8-K | $0.4480 $0.1165 | ▼ −74.00% | ▼ −76.98% | $0.2070 (−53.79%) |
Jun 11, 2026 19w ago | DEFA14A | $0.4192 $0.3290 | ▼ −21.52% | ▼ −23.41% | $0.2070 (−50.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers